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Abstract
Background: Studies examining whether genetic risk information about common, complex diseases can motivate
individuals to improve health behaviors and advance planning have shown mixed results. Examining the influence
of different study recruitment strategies may help reconcile inconsistencies.
Methods: Secondary analyses were conducted on data from the REVEAL study, a series of randomized clinical trials
examining the impact of genetic susceptibility testing for Alzheimer’s disease (AD). We tested whether self-referred
participants (SRPs) were more likely than actively recruited participants (ARPs) to report health behavior and
advance planning changes after AD risk and APOE genotype disclosure.
Results: Of 795 participants with known recruitment status, 546 (69%) were self-referred and 249 (31%) had been
actively recruited. SRPs were younger, less likely to identify as African American, had higher household incomes,
and were more attentive to AD than ARPs (all P <0.01). They also dropped out of the study before genetic risk
disclosure less frequently (26% versus 41%, P <0.001). Cohorts did not differ in their likelihood of reporting a change
to at least one health behavior 6 weeks and 12 months after genetic risk disclosure, nor in intentions to change at
least one behavior in the future. However, interaction effects were observed where ε4-positive SRPs were more
likely than ε4-negative SRPs to report changes specifically to mental activities (38% vs 19%, p < 0.001) and diets
(21% vs 12%, p =0.016) six weeks post-disclosure, whereas differences between ε4-positive and ε4-negative ARPs
were not evident for mental activities (15% vs 21%, p=0.413) or diets (8% versus 16%, P=0.190). Similarly, ε4-positive
participants were more likely than ε4-negative participants to report intentions to change long-term care insurance
among SRPs (20% vs 5%, p<0.001), but not ARPs (5% versus 9%, P=0. 36 5) .
Conclusions: Individuals who proactively seek AD genetic risk assessment are more likely to undergo testing and use
results to inform behavior changes than those who respond to genetic testing offers. These results demonstrate how
the behavioral impact of genetic risk information may vary according to the models by which services are provided,
and suggest that how participants are recruited into translational genomics research can influence findings.
Trial registration: ClinicalTrials.gov NCT00089882 and NCT00462917
Background
Genetic testing is increasingly accessible in both clinical
settings and the consumer marketplace, and hopes per-
sist that disclosure of genetic predispositions for disease
will empower individuals to change behaviors to reduce
their disease risks. While a number of studies have sug-
gested that there is little in the way of significant health
behavior change following genetic testing for common
diseases [1,2], a notable exception has been genetic sus-
ceptibility testing for Alzheimer’s disease (AD). Multiple
separate trials conducted as part of the Risk Evaluation
and Education for Alzheimer’s Disease (REVEAL) study
have shown that cognitively normal adults with an af-
fected parent or sibling who learned of an increased gen-
etic risk for AD are more likely than those at population
risk or those receiving non-genetic risk assessments to
report changes in putative AD-prevention behaviors [3,4].
Furthermore, the study showed that individuals who learn
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changes to advance planning [5,6]. These findings have led
commentators to cite AD genetic susceptibility testing as
an example of the personal utility genetic risk assessments
can provide [7-9].
The inconsistencies between REVEAL study findings
and research from the field at-large raises questions
about what may differ between studies. Certainly, the
lack of well-proven prevention and treatment strategies
distinguishes AD from other common diseases, but the
public tends to believe that lifestyle, diet, and mental ac-
tivity are important determinants of AD risk [10]. It is
also possible that the REVEAL study enrolled partici-
pants who were more motivated to pursue lifestyle mod-
ifications than other studies. While nearly all studies of
genetic risk disclosure have enrolled self-selected popu-
lations [1], the REVEAL study is distinctive in its pro-
portion of participants who self-referred to the study
compared to the proportion who were actively recruited.
Individuals who self-refer to an intervention not only
tend to have stronger personal and family histories of
disease [11-14] and stronger concerns about developing
the disease [11], but are also more likely to engage in
intervention activities [15,16]. These factors may help
explain why self-referred populations are frequently more
likely to report behavior changes following an intervention
than actively recruited populations [12,15].
Understanding how individuals who proactively seek a
genetic risk assessment may differ from individuals who
are responding to investigator-driven offers of testing
may help reconcile inconsistent findings across studies
and inform future models for genetic services. The ana-
lysis that follows compared self-referred participants
(SRPs) and actively recruited participants (ARPs) from
the second and third trials of the REVEAL study. First,
we examined the characteristics of each enrolled cohort,
expanding upon analyses of data from the first REVEAL
study trial – which enrolled ARPs exclusively from
research registries – by comparing a wider range of
demographic and psychosocial characteristics. We then
compared the percentage of participants who received a
genetic risk assessment. Finally, we examined associa-
tions between SRPs and ARPs in terms of their behav-
ioral outcomes, namely changes to mental activities, diet,
exercise, dietary supplement use, medications, long-term
care insurance coverage, and retirement plans. We hy-
pothesized that self-referred participants would be more
likely to report changes to health behaviors and advance
planning than ARPs.
Methods
Overview and study population
We conducted secondary analyses on data from the
REVEAL study, a series of multicenter randomized
controlled trials examining the psychological and behav-
ioral impact of providing AD genetic risk information
based on APOE genotyping [17-19]. Analyses were con-
ducted on data from the second and third study trials
(data from the first trial were omitted because the scales
and timing used to measure health behavior changes and
beliefs about AD and genetic testing greatly differed from
those used in the second and third trials). In each trial,
study sites recruited participants through a combin-
ation of strategies described in more detail below. In-
dividuals with two or more AD-affected first degree
relatives (FDRs), from families where the average AD
onset age was under 60 years, or who scored below an
education-adjusted 87 on the Modified Mini-Mental State
Examination [20] were excluded from participation. Indi-
viduals with severe psychiatric disorders, defined as scor-
ing above 25 on the Beck Anxiety Inventory [21] or above
26 on the Center for Epidemiological Studies-Depression
Scale [22], were also excluded. In the second trial, which
tested condensed education and disclosure protocols,
eligibility criteria required all participants to have a single
AD-affected FDR. In the third trial, which compared phone
versus in-person disclosure as well as disclosing pleiotropic
versus AD-only information, approximately 25% of partici-
pants had no AD-affected FDRs, while 75% had one AD-
affected FDR. A more comprehensive overview of the
REVEAL study has been published previously [17].
Study design
The multidisciplinary REVEAL study group designed
the study protocol and risk disclosure procedures,
which was reviewed by an external advisory board. The
Boston University Medical Campus Institutional Review
Board (IRB), Howard University Medical IRB, University
Hospitals IRB, University of Michigan Medical School IRB,
and Weill Cornell Medical College IRB approved the final
protocol, Participants provided informed consent by tele-
phone at the time of study enrollment, then again in writ-
ing prior to the blood draw for genotyping.
After completion of a phone interview and written
pre-education questionnaire, participants received edu-
cation about testing. Participants received information
(shown in Additional file 1) about (i) the definition of
AD; (ii) general risk factors for AD and the general pop-
ulation’s level of risk; (iii) APOE genotype and its impli-
cations for risk of AD; (iv) procedures involved in APOE
testing; (v) a preview of what would be provided in their
risk assessment; and (vi) known benefits, risks, and limi-
tations of APOE genotype testing, including the potential
for companies and employers to ask for results and ‘deny
insurance coverage or change your policy rates’ [23]
(materials were not revised after the passage of the
Genetic Information Nondiscrimination Act given ongoing
concerns about disability and long-term care insurance
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a genetic counselor. Those still interested in pursuing a
genetic risk assessment provided blood, which was geno-
typed at a Clinical Laboratory Improvement Amendments
(CLIA)-certified facility. Approximately one month after
the blood draw, participants received risk curves tailored
to their gender, race, AD family history (whether or not
the participant had an AD-affected FDR), and genotype
[25,26]. They were also told their APOE genotype and nu-
meric estimates of their cumulative lifetime (potential
range: 6% to 73%) and remaining risk for AD (cumulative
incidence from current age to the age of 85 years). Follow-
ing genetic risk disclosure, REVEAL study researchers
followed participants for the period of one year.
Measures
Demographic characteristics
Participants self-reported all demographic characteris-
tics, including age, race, gender, education, income, em-
ployment status, and number of AD-affected relatives.
All information was collected at the point of enrollment
except for education, income, and employment status,
which were collected during the phone interview.
Recruitment cohort
At enrollment, study staff queried participants about
how they ‘heard about the REVEAL study.’ The coordin-
ator or assistant then categorized verbal responses at the
time of enrollment into one of seven response categor-
ies: (a) ‘From another research study at this hospital,’
(b) ‘Someone from the study talked to me in the wait-
ing room,’ (c) ‘Someone from the study called me at
home or work,’ (d) ‘From a brochure or advertisement,’
(e) ‘Someone from the study gave a presentation,’ (f) ‘From
a friend,’ or (g) ‘Other,’ with open-ended descriptions that
were classified later (Table 1). Subjects were recoded as
SRPs if the participant initiated the enrollment interaction
(for example, called after reading about the study in the
newspaper or on a website) or ARPs if REVEAL study
personnel initiated the enrollment discussion (for ex-
ample, contacted through a research registry, approached
in neurology waiting room). Participants lacking data
about recruitment were classified as ‘unknown’ and omit-
ted from cohort comparisons.
Beliefs about Alzheimer’s disease and genetic testing
During enrollment, participants verbally provided the
following data.
Perceived susceptibility. Participants responded to the
question,‘On a scale of 0 to 100%, what do you think
your chance of developing AD during your lifetime is?’
in the second trial and ‘Out of 100 people just like you,
how many of them do you think will develop AD in
their lifetime?’ in the third. Analyses of perceived
susceptibility are stratified by trial given these differences
in wording.
Perceived seriousness. Participants rated their agreement
with the statement,‘AD is the worst disease I can think
of,’ on a five-point scale from strongly disagree (1) to
strongly agree (5).
Alzheimer’s disease concern. Participants rated their
agreement to statements on a four-item scale
(Cronbach α =0.65) implemented in prior research on
FDRs of AD patients [10]. Items included statements
such as ‘I am concerned that I will develop AD’ and ‘I
believe that I will someday develop AD.’ Higher scores
signified greater AD concern.
Interest. Study staff asked participants,‘In general, do you
t h i n ky o uw o u l db ei n t e r e s t e di nh a v i n gag e n e t i ct e s tt o
assess your chance of developing AD?’ Responses were
dichotomized as ‘yes’ versus ‘no’ and ‘maybe’combined.
During the telephone interview, participants verbally
provided the following data.
Alzheimer’s disease attentiveness. Participants responded
to the question, ‘Presently, how often do you think
about getting AD?’ on a four-point scale from 1
(not at all/rarely) to 4 (a lot).
Coping self-efficacy. On an open-ended question,
participants rated their certainty that they would be
able to cope with receiving a genetic test result that
indicated an increased chance of developing AD
from 0% (certain that they could not cope) to 100%
(certain that they could cope).
Participants provided the following data on the pre-
education questionnaire.
Perceived pros and cons. Participants rated the
importance of 11 reasons ‘why someone might take a
genetic test for AD’ (pros) and 10 reasons ‘why
someone might not want to take a genetic test for AD’
(cons) using scales developed from BRCA testing
research and analyzed previously (Cronbach’s α=0.83
for pros, 0.81 for cons) [27]. Scores on individual items
ranged from 1 (not at all important) to 5 (extremely
important), with means used in analyses.
Causal beliefs. Participants rated the importance of
‘genetics/heredity’ or ‘lifestyle (for example, diet, exercise,
smoking)’ for increasing one’s risk of AD. Scores ranged
from 1 (not important) to 5 (very important).
Expectations. The pre-education questionnaire asked,
‘What do you hope to get out of your risk assessment
experience?’ Participants checked yes or no about
expectations about receiving ‘reassurance’ and ‘help
in decision making.’
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Health behaviors
On a written questionnaire administered 6 weeks after
genetic risk disclosure, participants checked yes or no
about whether they had made changes to preventive
measures, including mental activities, diet, exercise, vita-
min usage, herbal supplement usage, and medications.
On the 12-month follow-up questionnaire, participants
indicated whether they were continuing changes re-
ported at 6 weeks, whether any new behavior changes
had been made since the 6-week follow up, and whether
they had plans to change behaviors in the future. Par-
ticipants were classified as having changed a behavior
at 12 months if they reported continuing a change re-
ported at 6 weeks or if they reported making a new
change between the 6-week follow-up and the 12-month
follow-up. Data on vitamin and herbal supplement usage
were combined and are reported as ‘dietary supple-
ments’ based on taxonomy used in administration of
the National Health and Nutrition Examination Survey
(NHANES) [28].
Advance planning
Participants checked yes or no on the 12-month follow-
up questionnaire about whether they had changed, or
planned to change, long-term care insurance coverage or
retirement plans related to the results of the genetic risk
assessment.
Prevention discussions
Study clinicians noted whether ‘preventative measures’
were discussed with participants during results disclos-
ure by checking the corresponding box on a chart note
completed at the end of each disclosure session.
Table 1 Sources for the self-referred and actively recruited cohorts
Classification Description n
Self-referred participants (n=546)
Brochure or advertisement Participants saw recruitment brochures that study staff left in neurology clinic waiting rooms
and related locations or responded to newspaper advertisements or flyers about the study
233
Media* Participants read about the study in a newsletter, newspaper article or book 91
Web site* Participants (a) found a website created at one of the participating study sites; (b) visited a
news or entertainment website that was discussing the REVEAL study; (c) found study details
on a website that helped studies enrol participants (for example, ClinicalTrials.gov); or (d) said
they had learned about the study ‘online,’‘ on the internet,’ or through a ‘Google search’
without being more specific
64
Study presentation Participants attended a community event to raise awareness about AD where study
personnel presented
49
Friend Participants learned about the study from acquaintances who were already participating or
heard about the study in the media
49
Acquaintance* Participants mentioned a specific individual who told them about the REVEAL study 37
Health fair* Participants approached a booth at a local health fair set up by Howard University 10
Wait list* Boston University waitlisted individuals who had wanted to participate in the first REVEAL
study trial
10
Self-referred* Study personnel labeled participants as ‘self-referred’ without elaboration 3
Actively recruited participants (n= 249)
Another research study Researchers specializing in neurology and AD discussed the REVEAL study with patients
enrolled in a separate study
149
Called at home or work Study personnel called individuals who provided contact information for research purposes,
usually through membership in a research registry
35
Provider referral* A nurse, physician, or genetic counselor referred the participant to the study 25
Mailing* Participants received mailings because they (a) had relatives who participated in the AD
Anti-Inflammatory Prevention Trial (ADAPT), (b) were members of the Michigan AD Research
Center registry, or (c) were members of the Michigan Dementia Coalition
15
Clinic intake* Howard University personnel classified individuals they had approached at neurology clinics
this way
12
Alzheimer’s Disease Center (ADC) referral* The Boston University ADC referred individuals to the REVEAL study who (a) wanted to
participate in another study that was already closed or for which they did not qualify, or
(b) accompanied AD-affected relatives to ADC appointments for another study
7
Approached in the waiting room REVEAL study personnel approached families in waiting areas of neurology and geriatrics clinics 6
*Classification was based on secondary coding of open-ended responses after an initial classification of ‘other.’
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Bivariate analyses using chi-squared tests, Wilcoxon
rank-sum tests, linear regression, and logistic regression
analyses were used to compare the demographic and
psychosocial profiles of SRPs and ARPs at baseline.
These techniques were also used for bivariate analyses
that identified factors associated with study dropout be-
fore disclosure of genetic risk information. Logistic re-
gression models, which controlled for demographic and
psychosocial factors that varied by recruitment cohort as
well as experimental variables (that is, randomization
status), were used to examine changes to health behav-
iors and advance planning, including tests for interaction
effects between cohort and genetic risk status. Logistic
regression, controlling for the same demographic and
experimental factors, was also used to test for differences
in continuation rates of behavior changes reported at
6 weeks, and also to test for differences in likelihood of
discussing preventive measures during the disclosure
session. Associations between genotype and behavioral
outcomes of interest were considered to differ by cohort
only if APOE-cohort interactions were significant at
α =0.05. Analyses did not account for multiple hy-
pothesis testing given that the studies were powered for
testing primary hypotheses about psychological outcomes
(that is, measures of anxiety and depression) rather than
the logistic regression analyses presented here.
Per protocol analyses were conducted using R version
3.1.1 such that tests for health behavior change analyses
included only participants who received genetic risk in-
formation [29]. We imputed item non-response using
fully conditional specification using R package mice 2.22
[30], running 20 iterations to create each of 100 imputed
datasets. Variables that were used to calculate joint prob-
abilities for multiple imputation of missing data from
the pre-education survey were selected using an in-
clusive strategy [31], and included recruitment cohort,
study round, dropout stage, demographic factors, and
psychosocial characteristics. Variables that were used to
calculate joint probabilities for multiple imputation of
missing behavioral data included all variables included in
final logistic regression models, as well as study dropout
stage.
Results
Cohort characteristics at enrollment
Across the two trials, 249 ARPs and 546 SRPs enrolled
in the study, with sources for each recruitment cohort
summarized in Table 1. Nearly half of SRPs reported
learning about the study from a brochure or advertise-
ment, whereas the majority of ARPs reported referral
from another research study at the same institution.
Twenty-two participants were missing information about
how they learned about the study and excluded from
cohort comparisons. Compared with participants who
were part of the ARP and SRP cohorts, the group of par-
ticipants missing recruitment information was more
likely to self-identify as African American (48% versus
21%, P < 0.001) and to have enrolled at the Howard
University site (45% versus 22%, P =0. 0 11 ) . T h ey
were less likely to have a college degree (45% versus 69%,
P= 0.023), to have household incomes of over $70,000
(29% versus 54%, P= 0.047) or to have enrolled at the Case
Western Reserve site (5% versus 24%, P=0.034).
Table 2 summarizes the demographic characteristics of
the SRP and ARP cohorts. SRPs tended to be younger,
less likely to self-identify as African American, and had
higher household incomes than ARPs. They were also
more likely to have enrolled at the Case Western Reserve,
Weill School of Medicine, and University of Michigan sites
and less likely to have enrolled at the Boston University
site. SRPs comprised a greater percentage of the third study
trial and a lower percentage of the second study trial.
F i n a l l y ,S R P sw e r em o r el i k e l yt ob ee m p l o y e dt h a n
ARPs, although retirees largely drove this difference:
39% of ARPs reported being retired compared with 22% of
Table 2 Descriptive statistics (number and percentage) of
REVEAL study participants by recruitment cohort
Characteristic Actively recruited
(n =249)
Self-referred
(n = 546)
P
Age ≥60 years 147 (59.0%) 223 (40.8%) <0.001
Male 87 (34.9%) 182 (33.3%) 0.666
Black/African American 86 (34.5%) 81 (14.8%) <0.001
College degree or higher* 130 (66.3%) 339 (70.0%) 0.343
Household income ≥$70 K* 83 (45.1%) 264 (57.1%) 0.006
Has an AD-affected first-degree
relative (parent or sibling)
216 (86.7%) 458 (83.9%) 0.297
Has an AD-affected family
member beyond first-degree
relatives
106 (44.2%) 281 (51.6%) 0.056
Employed part/full time* 99 (50.5%) 323 (66.9%) <0.001
ε4 carrier
† 46 (33.6%) 144 (37.1%) 0.459
Site by referral cohort <0.001
Boston University 122 (49.0%) 126 (23.1%)
Case Western Reserve 46 (18.5%) 145 (26.6%)
Howard University 63 (25.3%) 115 (21.1%)
Weill School of Medicine 11 (4.4%) 84 (15.4%)
University of Michigan 7 (2.8%) 76 (13.9%)
Trial by referral cohort <0.001
Second trial 160 (64.3%) 263 (48.2%)
Third trial 89 (35.7%) 283 (51.8%)
*Assessed during the telephone interview (196 actively recruited participants,
484 self-referred participants, 680 total).
†Determined through genotyping among participants who provided blood
samples (137 actively recruited participants, 388 self-referred participants,
525 total). P-values are bolded where differences between cohorts were
statistically significant.
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no differences between cohorts in randomization statuses,
nor in the likelihood of having an AD-affected FDR (ARP,
63%; SRP, 69%; P= 0.293). Cohorts also did not differ by
gender-age or gender-race combinations (P=0.566 and
0.692, respectively).
SRPs scored higher than ARPs on scales of AD con-
cern (3.5 versus 3.3, P =0.039) and were more likely to
declare interest in having a genetic test to assess AD risk
(94% versus 89%) in bivariate analyses of data collected
at enrollment, and scored higher on AD attentiveness
(2.1 versus 1.9, P <0.001) in bivariate analyses of data
collected during the phone interview (Additional file 2).
In addition, SRPs from the second trial scored higher
than ARPs on perceived susceptibility, although differ-
ences were not noted in the third trial. Only differences
in AD attentiveness (P<0.001) and perceived AD sus-
ceptibility among participants from the second trial (P =
0.011) remained significant in analyses of participants
who completed the pre-education questionnaire, how-
ever (Table 3).
Study dropout
ARPs were more likely to drop out of the REVEAL study
prior to genotype and AD risk disclosure than SRPs (41%
versus 26%, P<0.001). This association was still significant
(odds ratio=0.62, P= 0.011) in logistic regression analyses
that controlled for all data collected at intake (that is, race,
age, gender, interest, AD concern, perceived seriousness,
perceived susceptibility) and study-specific factors (trial
number, site). However, ARPs were no more likely than
SRPs to drop out once they completed the pre-education
questionnaire in unadjusted analyses (16% versus 13%, P
=0.286) or adjusted analyses (P=0.423).
Across cohorts, those who received genetic risk infor-
mation were more educated (P <0.001), had higher in-
comes (P< 0.001), and were less likely to identify as
female (P =0.015) or African American (P<0.001) than
participants who did not. Those who received test re-
sults were also more likely to have been enrolled at the
Weill School of Medicine and University of Michigan
sites (P <0.001; Additional file 3). Stratified analyses sug-
gested that younger participants, lower income, African
American race and site may have predicted dropout only
among the SRP cohort, although no interaction effects
between those factors and recruitment cohort were ob-
served (all P >0.110). The association between education
and test uptake was stronger among SRPs than ARPs
(P =0.031), but no other interactions between recruit-
ment cohort and demographic factors were observed
with respect to test follow-through. Bivariate analyses
also showed that individuals receiving genetic risk disclos-
ure had greater interest in having a genetic risk assessment
(P <0.001), perceived fewer cons of testing (P <0.001),
and had greater coping self-efficacy than participants
who dropped out (P < 0.001). Stratified analyses showed
that the association between perceived cons and study
dropout was borderline non-significant among ARPs
(P= 0.058), but were otherwise consistent with aggregated
data (Additional file 4).
Table 3 Beliefs about Alzheimer’s disease and genetic testing within each recruitment cohort among participants who
completed the pre-education questionnaire
Actively recruited (n= 163) Self-referred (n=444)
Continuous/ordinal measures (range) Mean± SD Mean± SD Δ (95% CI) P
Perceived susceptibility, second trial (0–100) 51.5±22.1 58.6±20.8 7.1 (1.7 to 12.6) 0.011
Perceived susceptibility, third trial (0–100) 35.5±25.3 34.0±21.3 −1.5 (1.7 to 12.6) 0.664
Perceived seriousness (1–5) 3.1±1.5 3.2 ±1.5 0.1 (−0.2 to 0.4) 0.389
AD concern (1–5) 3.4±0.8 3.5 ±0.7 0.1 (0.0 to 0.2) 0.122
AD attentiveness (1–4) 1.9±0.8 2.1 ±0.8 0.2 (0.1 to 0.4) 0.006
Coping self-efficacy (0–100) 86.3±19.4 86.0±18.7 −0.3 (−3.9 to 3.2) 0.861
Perceived pros (1–5) 3.5±0.8 3.5 ±0.7 0.0 (−0.1 to 0.1) 0.949
Perceived cons (1–5) 1.9±0.7 1.9 ±0.7 −0.1 (−0.2 to 0.0) 0.228
Causal belief: genetics/heredity (1–5) 4.1±0.9 4.1 ±0.9 0.0 (−0.2 to 0.1) 0.785
Causal belief: lifestyle (1–5) 3.5±1.2 3.4 ±1.1 −0.1 (−0.3 to 0.1) 0.525
Binary measures n (%) n (%) OR (95% CI) P
Interest in genetic risk assessment 159 (97%) 434 (98%) 1.2 (0.4 to 3.4) 0.779
Expectation of reassurance 19 (12%) 65 (15%) 1.3 (0.7 to 2.3) 0.412
Expectation of aided decision making 21 (13%) 58 (13%) 1.0 (0.6 to 1.8) 0.940
Results are adjusted for demographic factors that varied by cohort (age, race, income, employment status, study site, and study trial). CI, confidence interval; OR,
odds ratio.
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Overall, 33% of participants reported making a change
to at least one of the queried health behaviors at the
6 week follow-up, and 55% reported making a change at
the 12 month follow-up. Forty-seven percent reported
intention to change health behaviors in the future.
Across behaviors, recruitment mechanism was not asso-
ciated with likelihood of reporting a behavior change
(P= 0.319 at 6 weeks, P= 0.210 at 12 months) or intentions
to change behavior (P= 0.719). Analyses of specific behav-
iors found that self-referred participants were more likely
than ARPs to report changes to exercise at 12 months
(35% versus 25%, P=0.032). No other differences between
recruitment cohorts were noted on changes or plans to
change health behaviors.
Secondary analyses showed that the impact of genetic
risk status on certain behavior changes differed by recruit-
ment cohort, however. As Figure 1 shows, ε4-positive par-
ticipants were more likely than ε4-negative participants to
report changes at 6 weeks to mental activities and diet, but
only if they had self-referred to the study (APOE-cohort
interaction: P= 0.023 and 0.029, respectively), although
only differences in changes to mental activities persisted
through the 12 month follow-up. An interaction effect be-
tween ε4 status and recruitment cohort was also observed
on changes to medications at 12 months (P= 0.047). Iron-
ically, while nearly identical percentages of SRPs and ARPs
who were ε4-negative discussed prevention strategies with
the study clinician during the disclosure session (25% and
23%, respectively; P= 0.774), trends among ε4 carriers were
opposite than anticipated: 38% of the self-referred cohort
discussed prevention options compared with 54% of the
actively recruited cohort (P=0.053). Of additional note,
t h eS R Pc o h o r tw a sn om o r el i k e l yt oc o n t i n u eb e h a v i o r
changes reported at 6 weeks than the ARP cohort, even in
analyses that examined interactions between cohort and
APOE status (all P>0.05).
Similarly, 6% of participants reported a change to either
long-term care (LTC) insurance coverage or retirement
plans at the 12 month follow-up, while 16% reported inten-
tions to change advance planning. No direct associations
with self-referral were observed on either LTC insurance
coverage or retirement plans. An interaction effect was ob-
served (P= 0.005): self-referred ε4-positive participants
were more likely than ε4-negative participants to report in-
tentions to change LTC coverage, but no differences were
noted among ARPs (Figure 2). No associations were noted
on retirement plans, except greater intentions to change
among ε4-positive participants compared with ε4-negative
participants, regardless of recruitment cohort (P< 0.001).
Discussion and conclusions
This paper addresses the implications of different
study recruitment strategies on responses to genetic risk
information, using the model of APOE genotype disclos-
ure for risk of AD. While prior REVEAL study analyses
showed that ε4-positive participants were more likely than
ε4-negative participants to report changes to health behav-
iors and LTC insurance coverage [3-6], these follow-up
analyses show that such responses often depended upon
whether or not an individual had proactively sought test-
ing. ε4-positive participants were more likely to report
changes to mental activities, short-term changes to diet,
and plans to change LTC insurance coverage than ε4-
negative participants, but only if individuals had self-
referred into the study.
Our data do not fully explain why this difference is
present. Self-referred participants in the REVEAL study
may be more prepared to act on indications of increased
risk for AD. While few differences were observed at
baseline on beliefs about AD and attitudes about testing,
such factors represent only a fraction of the psychosocial
determinants that facilitate or inhibit behavior change.
Many have argued that risk assessment interventions fall
short by ignoring more critical determinants of behavior
change, especially motivation, behavioral capacity and
self-efficacy [32]. Supporting this notion was the finding
that self-referred individuals were less likely to discuss
prevention strategies during genetic risk disclosure, yet
more likely to respond to indications of increased gen-
etic risk. Interventions that hope to use genetic risk
information to motivate changes to lifestyles and other
behaviors may benefit from more careful consideration
of the readiness of individuals to enact such changes
[33]. Practitioners and researchers must also be sensitive
to the potential for studies of genetic risk information
to inflate its ability to motivate health behavior changes
by enrolling self-referred populations. Conclusions from
such studies may not apply to populations that are
less prone to proactively seek out genetic susceptibility
testing.
The implications of these findings are timely, given
advancements in technology to analyze genomes and
provide genetic susceptibility information. In particular,
great attention has been given to whether and how find-
ings from genomic sequencing and genetic research
should be disclosed, including calls to improve under-
standing of the impact of disclosing unsolicited genomic
risk information derived as incidental or secondary find-
ings [34-37]. In addition, questions persist about the utility
of direct-to-consumer genetic testing [38-40], which has
overwhelmingly relied on passive marketing strategies that
favor self-referral [41] (and companies have increasingly
incorporated APOE into their testing panels) [42]. The
results from our analyses underscore how the impact of
genomic information disclosure on lifestyles and advance
planning decisions may be very different under one model
of service provision than another.
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changes to health behaviors and advance planning, a
number of additional findings are of interest. As seen in
the first REVEAL study trial, SRPs tended to be younger
and had higher household incomes than ARPs [16].
They were also more likely to be employed, more inter-
ested in testing, and had greater attentiveness about AD
than ARPs. Of particular note - and contrary to findings
from the first REVEAL study trial, which enrolled ARPs
exclusively through research registries - was how SRPs
had less than half the percentage of African Americans
at intake. Prior research has found African Americans to
have less interest in hypothetical genetic testing for AD
[43] and actual genetic testing for susceptibility to other
diseases [44]. This finding underscores the need for ag-
gressive outreach if researchers hope to diversify the
samples enrolling in genetic susceptibility testing re-
search, while also suggesting caution when interpreting
racial differences in behavioral outcomes when tradition-
ally underrepresented groups are actively recruited. SRPs
were also more likely to progress from enrollment to
testing without dropping out, as found in analyses from
the first REVEAL study trial [16]. Studies favoring active
recruitment strategies should plan accordingly for
greater participant attrition.
A number of limitations should be mentioned. Differ-
ences in recruitment strategies also introduced differences
in sampling frames, complicating cohort comparisons.
Study measures had several limitations, including that be-
havioral outcomes were single-item self-reports of behavior
change and participant to social desirability biases [45].
Study participants, whether self-referred or actively re-
cruited, were highly educated volunteers with high socio-
economic status, and were positively inclined toward
genetic testing by virtue of their participation. As research
subjects, test results were omitted from medical records,
providing protections from discrimination that clinical test-
ing may not offer [24]. Statistical significance was set
at P =0.05 despite multiple comparisons, and findings
about changes to health behaviors would not have been
statistically significant at a more conservative value of
P =0.01. Analyzed data were collected over a 6-year
period that overlapped with advances in AD prevention
research [46], the emergence of direct-to-consumer gen-
etic testing [40], and the enactment of legislation prohi-
biting genetic discrimination [24] which could have
changed attitudes towards genetic susceptibility testing for
AD. Finally, the REVEAL study focused on single gene
testing for AD risk, and findings may not generalize well to
contexts where multiple genes and multiple diseases are
addressed.
Nevertheless, these analyses demonstrate how different
models of recruitment for providing genetic risk infor-
mation affect who pursues testing and how they respond
(See figure on previous page.)
Figure 1 Percentages of each recruitment cohort reporting changes to health behaviors, stratified by APOE status. Analyses examine
changes reported (A) 6 weeks and (B) 12 months after genetic risk disclosure, as well as (C) plans to change in the future. Analyses control for
demographic and psychological characteristics that varied by cohort (age, race, income, employment status, study round, randomization status,
site, perceived susceptibility and AD attentiveness). Error bars show 95% confidence intervals. Asterisks indicate an odds ratio (OR) cannot be
calculated because no ARPs who were ε4-negative reported changes to medications.
Figure 2 Percentages of each recruitment cohort reporting changes to advance planning outcomes, stratified by APOE status. Analyses
examine changes reported (A) 12 months after genetic risk disclosure, as well as (B) plans to change in the future. Analyses control for
demographic and psychological characteristics that varied by cohort (age, race, income, employment status, study round, randomization status,
site, perceived susceptibility and AD attentiveness). Error bars show 95% confidence intervals.
Christensen et al. Genome Medicine  (2015) 7:10  Page 9 of 11to the information they receive. Policymakers and clini-
cians will need to be sensitive to the ways genetic risk in-
formation can be obtained as they weigh its ability to
improve preventive behaviors and public health.
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